Summary & Overview
HCPCS J3374: Vancomycin Hydrochloride (Mylan) Injection, 10 mg
HCPCS Level II code J3374 designates a 10 mg unit of vancomycin hydrochloride (Mylan) for parenteral injection and is distinguished as not therapeutically equivalent to J3373. As an HCPCS Level II drug code, J3374 is used across outpatient settings to identify a specific manufacturer formulation for billing and reimbursement purposes. This clarity matters nationally because biologic and branded small-molecule variations can affect payer coverage, billing accuracy, and cost tracking for hospitals, infusion centers, and physician practices.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn how the code maps to clinical administration contexts, where it typically appears on claims, and what elements are available for benchmarking and policy review. The report presents a concise clinical context for use of vancomycin injections, the typical sites of service, and notes gaps where input data are unavailable. It also outlines common billing modifiers and other claim-level information separately where provided. This summary supports revenue cycle, compliance, and clinical teams seeking a national-level reference for accurate coding and claim preparation for vancomycin formulations labeled under J3374.
Billing Code Overview
HCPCS Level II code J3374 represents an injection of vancomycin hydrochloride (Mylan) supplied in a unit of 10 mg and is specified as not therapeutically equivalent to J3373. This code is used for billing administration of the specific branded/manufacturer-presented formulation identified in the description.
Service Type: Drug administration (intravenous or other parenteral antibiotic infusion/injection)
Typical Site of Service: Hospital outpatient department, physician office, infusion center, or other outpatient facility where parenteral antibiotics are administered
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A hospitalized adult patient with suspected or confirmed serious gram-positive infection (for example, methicillin-resistant Staphylococcus aureus bacteremia or complicated skin and soft tissue infection) requires intravenous glycopeptide therapy. The pharmacist verifies that the facility will use vancomycin hydrochloride product supplied under HCPCS code J3374 (vancomycin hydrochloride, 10 mg unit) which is designated as not therapeutically equivalent to J3373. The clinician orders weight-based dosing and therapeutic drug monitoring. Nursing prepares and administers the reconstituted medication via a peripheral or central intravenous line over an appropriate infusion time per institutional policy. Clinical workflow steps include order entry with indication and dose, pharmacy verification and compounding, dose banding and labeling with J3374 units billed per 10 mg increment, nursing administration with infusion rate and site documentation, and serum trough or AUC monitoring (if applicable). Documentation includes the indication, dose in milligrams and corresponding number of J3374 units billed, administration route, infusion time, lot and expiration for drug accountability, and any infusion-related reactions that may require modifier reporting (for example, use of modifier 52 if dose is reduced or 59 if distinct procedural services are reported). Payors involved may include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare depending on patient coverage.